All In Biotech

Drug Trial Radar · NCT00182715

Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

A Three-Arm Randomised Controlled Trial Comparing Either Continuous Chemotherapy Plus Cetuximab or Intermittent Chemotherapy With Standard Continuous Palliative Combination Chemotherapy With Oxaliplatin and a Fluoropyrimidine in First Line Treatment of Metastatic Colorectal Cancer (COIN)

Last checked: Nov 19, 2026Latest source record: Sep 17, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 2,421 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,421

Planned (sponsor's estimate)

Start

Mar 2005

Primary completion

May 2009

Sponsor

Lead sponsor
Velindre NHS TrustGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Sep 16, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether combination chemotherapy and cetuximab are more effective than combination chemotherapy alone in treating colorectal cancer. PURPOSE: This randomized phase III trial is studying combination chemotherapy and cetuximab to see how well they work compared to combination chemotherapy alone as first-line therapy in treating patients with metastatic colorectal cancer.

Conditions

  • Colorectal Cancer

Interventions

  • cetuximabBiological

  • capecitabineDrug

  • fluorouracilDrug

  • leucovorin calciumDrug

  • oxaliplatinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival at 2 years

Locations

82 sites in 2 countries. Site status is shown where the registry gives one.

  • Mercy University Hospital

    Cork, Ireland

  • Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital

    Dublin, Ireland

  • St. Vincent's University Hospital

    Dublin, Ireland

  • Mater Misericordiae University Hospital

    Dublin, Ireland

  • Mater Private Hospital

    Dublin, Ireland

  • St. James's Hospital

    Dublin, Ireland

  • Beaumont Hospital

    Dublin, Ireland

  • Galway University Hospital

    Galway, Ireland

  • Mid-Western Cancer Centre at Mid-Western Regional Hospital

    Limerick, Ireland

  • Waterford Regional Hospital

    Waterford, Ireland

  • North Hampshire Hospital

    Basingstoke, England, United Kingdom

  • Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust

    Birmingham, England, United Kingdom

  • Blackpool Victoria Hospital

    Blackpool, England, United Kingdom

  • Royal Bournemouth Hospital NHS Trust

    Bournemouth, England, United Kingdom

  • Bradford Royal Infirmary

    Bradford, England, United Kingdom

  • Sussex Cancer Centre at Royal Sussex County Hospital

    Brighton, England, United Kingdom

  • Bristol Haematology and Oncology Centre

    Bristol, England, United Kingdom

  • Queen's Hospital

    Burton-on-Trent, England, United Kingdom

  • West Suffolk Hospital

    Bury St Edmunds, England, United Kingdom

  • Addenbrooke's Hospital

    Cambridge, England, United Kingdom

  • Cumberland Infirmary

    Carlisle, England, United Kingdom

  • Cheltenham General Hospital

    Cheltenham, England, United Kingdom

  • Essex County Hospital

    Colchester, England, United Kingdom

  • Derbyshire Royal Infirmary

    Derby, England, United Kingdom

  • Dorset County Hospital

    Dorchester, England, United Kingdom

  • Eastbourne District General Hospital

    Eastbourne, England, United Kingdom

  • Princess Alexandra Hospital

    Essex, England, United Kingdom

  • St. Luke's Cancer Centre at Royal Surrey County Hospital

    Guildford, England, United Kingdom

  • Huddersfield Royal Infirmary

    Huddersfield, West Yorks, England, United Kingdom

  • Princess Royal Hospital at Hull and East Yorkshire NHS Trust

    Hull, England, United Kingdom

  • Hinchingbrooke Hospital

    Huntingdon, England, United Kingdom

  • Cookridge Hospital

    Leeds, England, United Kingdom

  • Aintree University Hospital

    Liverpool, England, United Kingdom

  • Saint Bartholomew's Hospital

    London, England, United Kingdom

  • Helen Rollason Cancer Care Centre at North Middlesex Hospital

    London, England, United Kingdom

  • University College of London Hospitals

    London, England, United Kingdom

  • Royal Free and University College Medical School

    London, England, United Kingdom

  • Queen Elizabeth Hospital - Woolwich

    London, England, United Kingdom

  • Cancer Research UK Clinical Groups at Guy's King's & St. Thomas' Hospitals

    London, England, United Kingdom

  • St. George's Hospital

    London, England, United Kingdom

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.